Pan-cancer analysis of progression-free survival (PFS) revealed that TMEM44 was an independent predictor in ACC, ESCA, KIRC, LIHC, and MESO based on COX analysis (P < 0.05) (Fig. 2A). Here, TMEM44 is linked to cancer.